Malignant Solid Tumors Clinical Trials

30 recruitingLast updated: June 18, 2026

There are 30 actively recruiting malignant solid tumors clinical trials across 5 countries. Studies span Phase 1, Phase 2, Not Applicable, Early Phase 1. Top locations include Beijing, Beijing Municipality, China, Shanghai, Shanghai Municipality, China, Nashville, Tennessee, United States. Updated daily from ClinicalTrials.gov.


Malignant Solid Tumors Trials at a Glance

30 actively recruiting trials for malignant solid tumors are listed on ClinicalTrialsFinder across 6 cities in 5 countries. The largest study group is Phase 1 with 18 trials, with the heaviest enrollment activity in Beijing, Shanghai, and Nashville. Lead sponsors running malignant solid tumors studies include Peking University Cancer Hospital & Institute, Shanghai Junshi Bioscience Co., Ltd., and Suzhou Suncadia Biopharmaceuticals Co., Ltd..

Browse malignant solid tumors trials by phase

Treatments under study

About Malignant Solid Tumors Clinical Trials

Looking for clinical trials for Malignant Solid Tumors? There are currently 10 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Malignant Solid Tumors trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Malignant Solid Tumors clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 30 trials

Recruiting

Natural History and Biospecimen Acquisition for Children and Adults With Rare Solid Tumors

Solid TumorPediatric Solid TumorMalignant Solid Tumors+2 more
National Cancer Institute (NCI)10,000 enrolled3 locationsNCT03739827
Recruiting
Phase 1

CT-95 in Advanced Cancers Associated With Mesothelin Expression

Colorectal, CancerMesothelin-Expressing TumorsEpithelial Ovarian Cancer+8 more
Context Therapeutics Inc.70 enrolled9 locationsNCT06756035
Recruiting
Phase 1Phase 2

A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors

Locally Advanced or Metastatic Malignant Solid Tumors
Astellas Pharma Global Development, Inc.428 enrolled7 locationsNCT07287995
Recruiting
Phase 2

Phase II Study of Asciminib for Second-line Treatment of Chronic Phase Chronic Myeloid Leukemia

Malignant Solid Tumors
M.D. Anderson Cancer Center40 enrolled1 locationNCT06629584
Recruiting
Phase 2

Phase II Study of JS212/JS213 as Monotherapy and in Combination in Patients With Advanced Malignant Solid Tumors

Advanced malignant solid tumors
Shanghai Junshi Bioscience Co., Ltd.410 enrolled1 locationNCT07480733
Recruiting
Phase 1

A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX43 in Advanced/Metastatic Solid Tumors

Advanced/Metastatic Malignant Solid Tumors
Shanghai Henlius Biotech367 enrolled10 locationsNCT06115642
Recruiting
Phase 1Phase 2

A Study of TAK-505 in Adults With Solid Tumors

Malignant Solid Tumors
Takeda151 enrolled15 locationsNCT07436728
Recruiting
Phase 1

Trial to Assess the Safety and Antitumor Activity of GEN1057 in Malignant Solid Tumors

Advanced malignant solid tumorsMetastatic Malignant Solid Tumors
Genmab45 enrolled5 locationsNCT06573294
Recruiting
Phase 1

Clinical Trial of IL - 22BP Safety, Tolerability, and Antitumor Activity in Refractory Solid Tumors.

Refractory Malignant Solid TumorsmRNA VaccineInterleukin
West China Hospital6 enrolled2 locationsNCT07040943
Recruiting
Not Applicable

Anti-HER2 CAR-T Cell Injection in Patients With HER2-positive Advanced Malignant Solid Tumors

HER2-positive Advanced Malignant Solid Tumors
UTC Therapeutics Inc.30 enrolled1 locationNCT06658951
Recruiting
Phase 1Phase 2

A Study of FC084CSA in Combination of Tislelizumab in Patients With Advanced Malignant Solid Tumors

Advanced malignant solid tumors
FindCure Biosciences (ZhongShan) Co., Ltd.33 enrolled1 locationNCT06499350
Recruiting
Phase 2

A Trial of SHR-4849 Combined With Other Antitumor Drugs in Patients With Malignant Solid Tumors

Malignant Solid Tumors
Suzhou Suncadia Biopharmaceuticals Co., Ltd.120 enrolled1 locationNCT07028281
Recruiting
Phase 1

A Study of CSCJC3456 in Patients With Advanced Malignant Tumors

Advanced malignant solid tumors
Changshan ConjuChem BioPharmaceutical Research and Development (Hebei) Co., Ltd.102 enrolled2 locationsNCT06717750
Recruiting
Phase 2

A Trial of SHR-7787 Injection Combined With Other Anti-tumor Drugs in Patients With Malignant Solid Tumors

Malignant Solid Tumors
Shanghai Hengrui Pharmaceutical Co., Ltd.400 enrolled2 locationsNCT07268040
Recruiting
Phase 1Phase 2

A Phase I/II Clinical Study of SHR-1681 for Injection in Patients With Advanced Solid Tumors

Malignant Solid Tumors
Suzhou Suncadia Biopharmaceuticals Co., Ltd.300 enrolled1 locationNCT06737731
Recruiting
Phase 1

A Clinical Trial Evaluating IL-22BP/LNP Compound in Refractory Malignant Solid Tumors for Safety, Tolerability and Activity

Refractory Malignant Solid TumorsmRNA VaccineInterleukin
Xingchen Peng6 enrolled1 locationNCT07100210
Recruiting
Phase 1

JSKN022 in Subjects With Advanced Malignant Solid Tumors

Advanced malignant solid tumors
Jiangsu Alphamab Biopharmaceuticals Co., Ltd225 enrolled1 locationNCT07292402
Recruiting
Not Applicable

Characterization of Hyperpolarized Pyruvate MRI Reproducibility

Malignant Solid Tumors
Memorial Sloan Kettering Cancer Center109 enrolled2 locationsNCT02421380
Recruiting
Not Applicable

Anti-Mesothelin CAR-T Cell Injection in Patients With Mesothelin-positive Advanced Malignant Solid Tumors

Mesothelin-positive Advanced Malignant Solid Tumors
Zhejiang University24 enrolled1 locationNCT07010523
Recruiting
Phase 1

MT027 in Patients With Advanced Peritoneal Malignancies or Abdominal Metastatic Solid Tumors

B7-H3-positive Advanced Malignant Solid Tumors Advanced Primary Peritoneal Tumors or Secondary Abdominal Metastatic Malignant Solid Tumors
Zhejiang University12 enrolled1 locationNCT06912152